Zymeworks (NASDAQ:ZYME) Price Target Raised to $39.00

Zymeworks (NASDAQ:ZYME) had its price target hoisted by TD Cowen from $34.00 to $39.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Citigroup reissued a “market outperform” rating on shares of Zymeworks in a research note on Monday, October 26th. Jefferies Financial Group reiterated a “buy” rating and set a $52.00 price target on shares of Zymeworks in a research note on Friday, October 23rd. Truist Financial lifted their price target on Zymeworks from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday. B. Riley Financial restated a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. Finally, Wells Fargo & Company boosted their price objective on shares of Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Zymeworks has a consensus rating of “Moderate Buy” and an average price target of $42.67.

Zymeworks Stock Down 8.9%

NASDAQ:ZYME opened at $26.47 on Tuesday. The stock’s 50 day moving average price is $27.39 and its two-hundred day moving average price is $25.46. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 50.90 and a beta of 1.32. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The company had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. During the same quarter in the previous year, the company posted ($0.26) earnings per share. The business’s revenue was up 828.7% on a year-over-year basis. Equities research analysts expect that Zymeworks will post 1.31 EPS for the current year.

Insider Buying and Selling

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president owned 23,205 shares of the company’s stock, valued at $599,849.25. The trade was a 37.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Trading of Zymeworks

Institutional investors have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its holdings in shares of Zymeworks by 759.9% during the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after purchasing an additional 537,837 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Zymeworks by 104.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock valued at $2,596,000 after acquiring an additional 50,127 shares during the last quarter. Calamos Advisors LLC purchased a new position in shares of Zymeworks in the 3rd quarter worth $1,232,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zymeworks during the 3rd quarter valued at approximately $96,000. Finally, ProShare Advisors LLC raised its holdings in Zymeworks by 91.5% during the 3rd quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock valued at $434,000 after buying an additional 7,833 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks News Roundup

Investors following ZYME have been watching these news items:

• Positive Sentiment: Citigroup raised its price target to $44 from $39 and maintained a Buy rating. Truist also forecast strong price appreciation, while TD Cowen lifted its target, adding to the positive analyst outlook. Truist Financial Forecasts Strong Price Appreciation for Zymeworks Zymeworks Stock Gets Price Target Boost from TD Cowen
• Positive Sentiment: Zymeworks recently reported better-than-expected earnings and reached a 52-week high, suggesting strong results had supported investor demand. Zymeworks Hits New 52-Week High After Better-Than-Expected Earnings
• Negative Sentiment: HC Wainwright cut estimates across several upcoming quarters and reduced its FY2026 EPS forecast to $1.19 from $1.51. Its FY2027 outlook shifted from expected earnings of $1.32 per share to a loss of $0.39 per share. These substantial revisions are a negative near-term signal, although the firm kept its Buy rating and $56 target. Zymeworks analyst and stock information

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.